Key Points
- DexCom EVP Michael Jon Brown sold 1,700 shares on May 15 at an average price of $59.91, a transaction worth about $101,847. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the sale, Brown still held 109,504 shares of DexCom, valued at roughly $6.56 million, and the trade reduced his ownership by just 1.53%.
- DexCom recently reported better-than-expected quarterly results, with EPS of $0.56 versus the $0.47 consensus and revenue of $1.19 billion, while analysts currently view the stock as a Moderate Buy with a consensus target of $82.21.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $59.91, for a total value of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares in the company, valued at approximately $6,560,384.64. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $63.04, for a total value of $107,168.00.
- On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00.
DexCom Trading Up 2.9%
DXCM opened at $66.95 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The company's 50 day simple moving average is $63.33 and its two-hundred day simple moving average is $65.82. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The firm has a market capitalization of $25.83 billion, a price-to-earnings ratio of 28.61, a price-to-earnings-growth ratio of 1.12 and a beta of 1.40.
DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the company posted $0.32 EPS. The business's revenue was up 15.0% on a year-over-year basis. Analysts expect that DexCom, Inc. will post 2.56 EPS for the current fiscal year.
Institutional Investors Weigh In On DexCom
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company's stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC lifted its position in DexCom by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock valued at $727,842,000 after acquiring an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company's stock valued at $530,897,000 after acquiring an additional 516,526 shares during the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at $483,356,000. Finally, Invesco Ltd. lifted its position in DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company's stock valued at $352,781,000 after acquiring an additional 686,228 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Weiss Ratings raised shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Truist Financial restated a "buy" rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Robert W. Baird set a $80.00 price target on shares of DexCom in a research note on Friday, May 1st. Finally, TD Cowen dropped their price target on shares of DexCom from $84.00 to $75.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $82.21.
View Our Latest Report on DexCom
Key Headlines Impacting DexCom
Here are the key news stories impacting DexCom this week:
- Positive Sentiment: DexCom announced Dexcom Flex in Germany, expanding CGM access to a broader Type 2 diabetes population using basal insulin, oral medications, or GLP-1 therapies. Dexcom Announces Dexcom Flex in Germany
- Positive Sentiment: Bank of America lowered its price target to $80 from $100 but kept a buy rating, which still implies upside from current levels. Benzinga report on Bank of America price target
- Neutral Sentiment: Barclays reiterated its sell rating on DexCom, adding a bearish counterpoint that may limit enthusiasm. Barclays sticks to its sell rating
- Negative Sentiment: EVP Michael Jon Brown sold 1,700 shares in a pre-arranged Rule 10b5-1 transaction, which is routine but can still weigh on sentiment when investors are watching insider activity closely. SEC Form 4 filing
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
